Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- People who have been diagnosed with multiple myeloma (a type of blood cancer affecting plasma cells)
- People who are receiving a treatment called Teclistamab
- People who have signed a consent form agreeing to take part in the trial
Who may not be able to join:
- People who are under legal protection (such as guardianship or similar legal arrangements) (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hervé AVET LOISEAU, MD, PhD, University Hospital, Toulouse
Phone: +33 531 156 142
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Response to teclistamab at 12 weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.